Simple Summary Prostate cancer affects men of all racial and ethnic groups and leads to
higher rates of mortality in those belonging to a lower socioeconomic status due to late …

Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth
leading cause of death worldwide. Prostate cancer may be asymptomatic at the early stage …

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants …

PURPOSE To provide precise age-specific risk estimates of cancers other than female
breast and ovarian cancers associated with pathogenic variants (PVs) in BRCA1 and …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

Background PROpel met its primary endpoint showing statistically significant improvement
in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus …

Background Inherited mutations in DNA-repair genes such as BRCA2 are associated with
increased risks of lethal prostate cancer. Although the prevalence of germline mutations in …

PURPOSE Germline testing (GT) is a central feature of prostate cancer (PCA) treatment,
management, and hereditary cancer assessment. Critical needs include optimized …

Prostate cancer (PCa) is globally the second most diagnosed cancer type and the most
common cause of cancer-related deaths in men. Family history of PCa, hereditary breast …